Trials / Completed
CompletedNCT04337970
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
A Phase Ib/II Study of Talazoparib and Axitinib in Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes few or mild side effects when given in combination with a standard dose of axitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talazoparib | Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily Phase II: MTD to be determined. |
| DRUG | Axitinib | 5 mg PO BID |
Timeline
- Start date
- 2020-04-06
- Primary completion
- 2025-05-23
- Completion
- 2025-05-23
- First posted
- 2020-04-08
- Last updated
- 2025-05-28
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04337970. Inclusion in this directory is not an endorsement.